The historic rise of Viagra has consistently remained a benchmark of pharmaceutical success, yet its legacy within the broader market now raises questions about long-term returns . Generic versions are diminishing patent protection , causing concerns that betting on companies closely tied to Viagra's former influence could be a problematic decision